TempraMed to Commence Trading on the Canadian Securities Exchange Under Symbol "VIVI", Today, October 15, 2025
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange ("CSE"). Trading is expected to commence on CSE under symbol "VIVI" at the open of markets on October 15, 2025. Further, the board of directors (the "Board") of the Company announced today that it has received and accepted...
2025-10-15 7:00 AM EDT
TempraMed Receives Final Receipt for Prospectus and Closes Reverse Takeover Transaction of TempraMed Israel
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - TempraMed Technologies Ltd. (the "Company") is pleased to announce that the Company has filed and obtained a receipt on September 29, 2025, for its final long form prospectus dated September 25, 2025 (the "Prospectus"), with the British Columbia Securities Commission and is now a reporting issuer in the Province of British Columbia, effective as of September 29, 2025. The Prospectus was filed for, among other things, the...
2025-10-10 7:00 AM EDT
TempraMed Closes Oversubscribed C$7.4M Financing and Advances Toward Go Public Listing
Sammamish, Washington--(Newsfile Corp. - September 3, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator redefining how temperature-sensitive medications are stored, managed and protected, is pleased to announce significant corporate and capital markets milestones, including the successful close of an oversubscribed C$7.4 million private placement financing and strong progress toward its public listing on the Canadian Securities Exchange (CSE), expected...
2025-09-03 7:00 AM EDT
TempraMed Partners with the Diabetes Education & Camping Association of the USA (DECA), Supporting Safe Insulin Storage for Children at Diabetes Camps Across the United States
Sammamish, Washington--(Newsfile Corp. - August 7, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is proud to announce a new partnership with the Diabetes Education & Camping Association (DECA) by providing VIVI Cap devices to diabetes camps across the United States. As part of this partnership, TempraMed is providing these critical temperature-sensitive storage devices to support...
2025-08-07 7:00 AM EDT